San Diego, CA – July 28, 2020 – Nascent Biotech, Inc. (OTCQB.NBIO), announced today it has entered into a research collaboration with Syracuse University to further the development of Pritumumab, a unique monoclonal antibody that binds to cell-surface vimentin, for potential use in COVID-19 treatment.
Alison Patteson, an assistant professor of physics at Syracuse University, will test to see if Pritumumab has the potential to block SARS-CoV-2 (SARS2), the virus responsible for COVID-19, from entering cells. According to Patteson, research shows that SARS2 may be traveling into cells by way of a receptor known as cell-surface vimentin (CSV). This ia a protein found on the cell surface, similar to vimentin, which is a key internal structural protein present in many cell types. Vimentin is known for its cage-like structure which protects the cell against damage..
“Our hope is that when we treat cells with Pritumumab, it will bind to CSV, and effectively block the SARS2 virus from entering the cell,” says Patteson. “An antibody that could block the entry of SARS2 into the cell could be a monumental step in the fight against COVID-19.”
Patteson will test the hypothesis on mouse embryo fibroblast cells and lung airway epithelial cells to determine if the antibody will block the uptake of SARS2. Using a cell in which vimentin has been knocked out, the results will provide an important control of Pritumumab effects.
Nascent Biotech Chief Medical Officer over Viral Research, Dr. Navpaul Singh said, “This collaboration will determine if Pritumumab can effectively block SARS2 in an animal mouse model. It will also gauge Pritumumab’s ability to bind vimentin in a live model.”
About Nascent Biotech, Inc.:
Nascent Biotech, Inc is a clinical-stage biotech company engaged in the development of monoclonal antibodies to be used in the treatment of various cancers. Its products are not commercially available. For further information please visit our website www.nascentbiotech.com.
Statements in this press release about our future expectations constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, Nascent Biotech Inc’s ability to target the medical professionals; Nascent Biotech Inc’s ability to raise capital; as well as other risks. Additional information about these and other factors may be described in the Nascent Biotech Inc’s Form 10, filed on May 2, 2015, and future subsequent filings with the Securities and Exchange Commission. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
For further information, please contact:
Nascent Biotech, Inc
6330 Nancy Ridge Dr
San Diego CA 92121
Source: Nascent Biotech, Inc